Literature DB >> 10494001

Site dependent bioavailability and metabolism of levosimendan in dogs.

S Antila1, H Huuskonen, T Nevalainen, H Kanerva, P Vanninen, L Lehtonen.   

Abstract

Site specific bioavailability and metabolism of levosimendan was studied in ten dogs by placing intestinal access port catheters in different parts of the gastrointestinal tract. 14C-labelled levosimendan (0.1 mg/kg) was administered intravenously, by gastric tube and directly through catheters that were placed in the duodenum, jejunum and ileum. Plasma samples were collected and radioactivity in the different organs and tissues was measured. The results of the present study showed that bioavailability of levosimendan was high varying from 71 to 86% after extravascular administration. Metabolite OR-1855 concentrations in the plasma were about 3-4 times higher after administration to the ileum compared to the other administration routes. It can be concluded that the bioavailability of levosimendan is not affected by site specific administration. The bacteria or enzymes responsible for the metabolism of levosimendan are located in the lower parts of the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494001     DOI: 10.1016/s0928-0987(99)00048-2

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  12 in total

Review 1.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

Review 2.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

Review 3.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.

Authors:  L Lehtonen
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

Review 5.  Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.

Authors:  Lasse Lehtonen
Journal:  Curr Heart Fail Rep       Date:  2004-09

6.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 7.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Intranasal levosimendan prevents cognitive dysfunction and apoptotic response induced by repeated isoflurane exposure in newborn rats.

Authors:  Serdar Demirgan; Onat Akyol; Zeynep Temel; Aslıhan Şengelen; Murat Pekmez; Ozancan Ulaş; Mehmet Salih Sevdi; Kerem Erkalp; Ayşin Selcan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-27       Impact factor: 3.000

10.  The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia.

Authors:  Anna B Roehl; Norbert Zoremba; Markus Kipp; Johannes Schiefer; Andreas Goetzenich; Christian Bleilevens; Nikolaus Kuehn-Velten; Rene Tolba; Rolf Rossaint; Marc Hein
Journal:  BMC Neurol       Date:  2012-08-24       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.